Of note, our study showed that enrichment of CD4+ T and B cells correlated with favorable clinical outcomes in NSCLC, and that IL-21 is critical for tumor control and B cells class switching to anti-tumor IgG1 and IgG3 isotypes. The gene discussed is IGHG3; the disease is non-small cell lung carcinoma.